Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Triarylpyrazoles with basic side chains: development of pyrazole-based estrogen receptor antagonists.

S R Stauffer1, Y R Huang, Z D Aron

  • 1Department of Chemistry, University of Illinois and University of Illinois College of Medicine, Urbana 61801, USA.

Bioorganic & Medicinal Chemistry
|February 24, 2001
PubMed
Summary

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Corrigendum to "Comprehensive assessment of estrogen receptor beta antibodies in cancer cell line models and tissue reveals critical limitations in reagent specificity" [Mol. Cell Endocrinol. 440 (2016) 138-150].

Molecular and cellular endocrinology·2017
Same author

Extra-nuclear effects of estrogen on cortical bone in males require ERαAF-1.

Journal of molecular endocrinology·2017
Same author

OCT-4: a novel estrogen receptor-α collaborator that promotes tamoxifen resistance in breast cancer cells.

Oncogene·2016
Same author

Spatial mapping of juxtacrine axo-glial interactions identifies novel molecules in peripheral myelination.

Nature communications·2015
Same author

ESR1 and ESR2 differentially regulate daily and circadian activity rhythms in female mice.

Endocrinology·2014
Same author

Macrophage-elicited loss of estrogen receptor-α in breast cancer cells via involvement of MAPK and c-Jun at the ESR1 genomic locus.

Oncogene·2011

Researchers modified a pyrazole estrogen receptor (ER) agonist into an antagonist by adding a side chain. The C(5) substituted pyrazole 5 showed high affinity for ERalpha and acted as an antagonist, suggesting a new binding mode.

Area of Science:

  • Medicinal Chemistry
  • Molecular Pharmacology
  • Endocrinology

Background:

  • Novel triaryl-substituted pyrazole ligands exhibit high affinity for the estrogen receptor (ER).
  • Previous studies indicated selective ERalpha subtype agonism for some analogues.

Purpose of the Study:

  • To convert pyrazole ER agonists into antagonists or selective estrogen receptor modulators (SERMs).
  • To investigate the impact of basic side chains on ligand-receptor interactions and activity.
  • To determine optimal substitution sites for antagonist activity.

Main Methods:

  • Synthesis of four pyrazole analogues with N-piperidinyl-ethyl side chains at different positions.
  • Estrogen receptor binding affinity assays for ERalpha and ERbeta.
  • Cell-based transcription assays to determine agonist/antagonist activity.

Related Experiment Videos

  • Molecular modeling using the ERalpha-raloxifene crystal structure.

    • Main Results:

    • Pyrazole 5, with a C(5) piperidinyl-ethoxy substituent, demonstrated the highest affinity.
    • Compound 5 exhibited 20-fold greater affinity for ERalpha than ERbeta.
    • Pyrazole 5 functioned as an antagonist for both ERalpha and ERbeta, with greater potency on ERalpha.
    • Structure-binding relationships and modeling suggest a distinct binding mode for C(5) substituted pyrazoles.

    Conclusions:

    • Incorporating a basic side chain at the C(5) position of the pyrazole core can convert ER agonists into potent ER antagonists.
    • Pyrazole 5 displays selective antagonism for ERalpha, characteristic of a SERM.
    • The proposed binding mode involves the N(1) phenol in the A-ring pocket and the basic side chain mimicking raloxifene's orientation.